论文部分内容阅读
59例晚期非小细胞肺癌分别作VDS-DDP方案和CAP方案治疗，其中VDS-DDP方案27例，获CR1例，PR11例，有效率48．1％（12／27）；CAP方案32例，获CR1例，PR14例，有效率46．8％（15／32）。统计学分析两组无显著性差异。分析诸因素对疗效的影响，发现病期早较病期晚疗效好。生活质量评估Karnofsky评分VDS－DDP组升高为70．4％（19／27），CAP组为68．8％（22／32）。两组无显著性差异。骨髓抑制为限量性毒性，白细胞下降分别为74．1％和71．9％，但无1例发生感染，亦无其他严重毒副反应发生。作者认为，VDS－DDP方案与CAP方案一样，疗效确切，毒副反应轻，可作为治疗非小细胞肺癌的又一有效方案，而早期诊断和早期治疗是提高疗效的重要手段。
59 cases of advanced non-small cell lung cancer were treated with VDS-DDP regimen and CAP regimen respectively, including 27 cases of VDS-DDP regimen, 1 case of CR, 11 cases of PR, effective rate of 48.1% (12/27), and 32 cases of CAP regimen. CR1 cases, PR14 cases, effective rate 46.8% (15/32). Statistical analysis showed no significant difference between the two groups. Analyze the influence of various factors on the curative effect and find that the disease is better than the disease in the early stage. The quality of life assessment Karnofsky score in the VDS-DDP group was increased to 70.4% (19/27), and the CAP group was 68.8% (22/32). There was no significant difference between the two groups. Myelosuppression was limited toxicity, with leukopenia of 74.1% and 71.9%, respectively, but no infection occurred and no other serious adverse reactions occurred. The authors believe that the VDS-DDP regimen is as effective as the CAP regimen in that it has a definite curative effect and less side effects. It can be used as another effective treatment for NSCLC, and early diagnosis and early treatment are important means to improve the therapeutic effect.